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Boston, Massachusetts 02115 Smads are regulated by receptor-dependent phos-
phorylation that is highly specific. Smad2 and Smad3
interact with TGFb receptors (MacõÂas-Silva et al., 1996;
Summary Zhang et al., 1996), while Smad1 is targeted by BMP
pathways (Hoodless et al., 1996; Kretzchmar et al.,
TGFb signaling is initiated when the type I receptor 1997). Phosphorylation of Smads is mediated directly
phosphorylates the MAD-related protein, Smad2, on by the activated type I kinase domain and occurs on
C-terminal serine residues. This leads to Smad2 asso- serine residues within a conserved SSXS motif at the C
ciation with Smad4, translocation to the nucleus, and terminus of the protein (MacõÂas-Silva et al., 1996;
Kretzchmar et al., 1997). Phosphorylation of these re-regulation of transcriptional responses. Here we dem-
ceptor-regulated Smads results in formation of a hetero-onstrate that Smad7 is an inhibitor of TGFb signal-
meric complex with another MAD-related protein,ing. Smad7 prevents TGFb-dependent formation of
Smad4 (Kretzchmar et al., 1997). Thus, Smad1, 2, 3, andSmad2/Smad4 complexes and inhibits the nuclear
5 appear to play specific roles in these pathways, whileaccumulation of Smad2. Smad7 interacts stably with
Smad4 fulfills a common function (Lagna et al., 1996;the activated TGFb type I receptor, thereby blocking
Zhang et al., 1997). Phosphorylation of Smads is re-the association, phosphorylation, and activation of
quired for their accumulation in the nucleus (MacõÂas-Smad2. Furthermore, mutations in Smad7 that inter-
Silva et al., 1996; Kretzchmar et al., 1997) where thefere with receptor binding disrupt its inhibitory activity.
proteins can function as transcriptional activatorsThese studies thus define a novel function for MAD-
through their interaction with DNA-binding proteins. Forrelated proteins as intracellular antagonists of the type
instance, in Xenopus, Smad2 interacts with the fork-I kinase domain of TGFb family receptors.
head-containing DNA-binding protein, FAST1, to acti-
vate the activin responsive element in the mix.2 gene
Introduction (Chen et al., 1996). This signaling pathway thus provides
a direct link between the receptor kinase and the tran-
Members of the transforming growth factor b (TGFb) scriptional machinery required to mediate the biological
superfamily play a critical role in regulating cellular response to ligand.
growth and differentiation in a wide range of biological The biochemical and functional characterization of
systems. These polypeptide growth factors signal Smad1±5 as downstream mediators of TGFb superfam-
through heteromeric complexes of type I and type II ily signaling is yielding a comprehensive view of how
transmembrane Ser/Thr kinase receptors (Attisano and this signaling pathway may function. However, novel
Wrana, 1996; Weis-Garcia and Massague, 1996). Activa- Smads with unknown functions have been identified in
tion of the receptor complex occurs when the type II the expressed sequence tag (EST) database or in
receptor kinase transphosphorylates the GS domain of screens unrelated to TGFb signaling. We now investi-
the type I kinase (Wrana et al., 1994). This activates gate the MAD-related protein Smad7 which is induced
the type I kinase, which transiently associates with and by laminar fluid shear stress and is expressed at ele-
vated levels in the vascular endothelium (Topper et al.,phosphorylates a unique family of intracellular signaling
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1996, 1997). We demonstrate that expression of Smad7
in TGFb-responsive cells suppresses ligand-dependent
signaling. Smad7 directly interferes with TGFb-medi-
ated activation of Smad2 by preventing its phosphoryla-
tion, interaction with Smad4, and nuclear accumulation.
Smad7 functions by associating stably with the acti-
vated TGFb type I receptor to block access and phos-
phorylation of Smad2. Thus, Smad7 defines a novel
class of MAD-related proteins that inhibit Ser/Thr kinase
receptor signaling by acting as intracellular antagonists
of the type I receptor kinase domain.
Results
Smad7 Inhibits TGFb Signaling
The MAD-related protein Smad7 was isolated ina screen
to identify genes that are induced when endothelial cells
are placed under laminar fluid shear stress (Topper et
al., 1996) and is represented in the expressed sequence
tag database. Smad7, which possesses MH1 and MH2
domains, lacks an SSXS motif at the C terminus (Topper
et al., 1997), suggesting that the protein is not a target for
receptor phosphorylation and may fulfill an undescribed
function in Ser/Thr kinase receptor signaling.
We first tested the potential role of Smad7, by investi-
gating the effects of its expression on TGFb signaling.
For these studies, we utilized HepG2 and Mv1Lu cells,
both of which possess receptors and are TGFb respon-
sive. Initially, we focused our analyses on p3TP-Lux,
Figure 1. TGFb-Induced Transcriptional Activation of the 3TP Pro-which contains elements from the PAI-1 promoter, is
moter Is Inhibited by Smad7TGFb responsive, and drives expression of a luciferase
HepG2 (A) or Mv1Lu (B) cells were transiently transfected with p3TP-reporter gene (Wrana et al., 1992). Transient transfection
Lux alone or with wild-type (WT) or activated (A) TbRI in the absenceof p3TP-Lux into either HepG2 or Mv1Lu cells resulted
or presence of Smad7. Cells were incubated overnight in the ab-
in low basal levels of transcription in untreated cells, sence or presence of 100 pM of TGFb, and the relative luciferase
which was strongly induced by stimulation with 100 pM activity was measured in cell lysates. Luciferase activity was normal-
TGFb (Figure 1). In cells cotransfected with Smad7, there ized to b-galactosidase activity and is expressed as the mean 6
SD of triplicates from a representative experiment.was little effect on basal transcription; however, we ob-
served a strong suppression of TGFb-dependent induc-
tion of the 3TPpromoter. TGFb signaling can be initiated DNA-binding protein, FAST1, and activation of tran-
by expression of a constitutively active version of the scription from anactivin-responsive element (ARE; Chen
TGFb type I receptor, TbRI, which contains a substitu- et al., 1996). Since Smad2 functions in both TGFb- and
tion of threonine residue 204 to aspartate and signals activin-signaling pathways (Baker and Harland, 1996;
TGFb responses in the absence of ligand and the type II Eppert et al., 1996; Graff et al., 1996; MacõÂas-Silva et
receptor (Wieser et al., 1995). In both HepG2 and Mv1Lu al., 1996), we utilized this system to investigate the role
cells, transfection of activated TbRI led to strong stimu- of Smad7 in blocking immediate early responses to
lation of the 3TP promoter that was potently inhibited by TGFb. To establish that this assay functions in HepG2
coexpression of Smad7(Figure 1). Since oursubsequent cells, we constructed pAR3-lux, which contains a lucif-
biochemical analyses involved versions of Smad7 that erase reporter gene under the control of three AREs
were epitope tagged at the amino and carboxyl termini linked to a basic TATA box±containing promoter. This
with myc and HA epitopes, respectively, we also tested construct had minimal basal activity in HepG2 cells, but
the activity of the modified proteins. These versions of when it was cotransfected with FAST1, we observed a
Smad7 were indistinguishable from untagged proteins strong TGFb-dependent induction of the reporter gene
in blocking TGFb-dependent signaling in all of the (Figure 2A). These data indicate that HepG2 cells contain
assays that we employed (data not shown). Together, the necessary components to activate transcription
these data suggest that Smad7 can function to block from an ARE, but are missing the DNA-binding compo-
TGFb signaling downstream of its receptors. nent, FAST1. To determine whether Smad7 can block
To determine whether Smad7 inhibitory activity was activation of pAR3, HepG2 cells werecotransfected with
a direct effect on TGFb-signaling pathways, we devel- pAR3-Lux, FAST1, and Smad7. In contrast to the stimu-
oped an immediate early response assay for TGFb sig- lation observed in cells receiving only FAST1, TGFb-
naling. In Xenopus, activin signaling leads to the specific dependent activation was suppressed in cells cotrans-
fected with Smad7 (Figure 2A).association of Smad2 with the forkhead-containing
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either in thepresence or absence of Smad7. In untreated
cells, basal transcription from the reporter gene was
low and was unaffected by cotransfection with Smad7.
However, treatment of cells with 100 pM TGFb resulted
in a strong induction of the promoter in cells transfected
with GAL4/Smad2 alone. In contrast, cotransfection with
Smad7 resulted in almost complete abrogation of TGFb-
dependent activation of the promoter that was partially
reversed when higher doses of GAL4/Smad2 were trans-
fected into the cells. Together, these data suggest that
Smad7 may block TGFb responses by interfering di-
rectly with the signaling pathways.
Smad7 Blocks Activation of Smad2
TGFb signaling through Smad2 is initiated when the
type I receptor kinase, activated by receptor II±mediated
transphosphorylation, directly phosphorylates Smad2
on the C-terminal serine residues (MacõÂas-Silva et al.,
1996). This phosphorylation results in dissociation of
Smad2 from the receptor and is required for subsequent
interactions with Smad4 and nuclear translocation of
the protein (MacõÂas-Silva et al., 1996; Kretzchmar et al.,
1997). To investigate whether Smad7 interferes with any
of these signaling events, we determined if it could block
either Smad2 association with Smad4 or its nuclear ac-
cumulation. To investigate heteromeric complex forma-
tion, HepG2 cells were transiently transfected with
Smad2 and Smad4 either in the presence or absence
of Smad7. In cells expressing Smad2 and Smad4, no
association between these two proteins could be de-Figure 2. Smad7 Interferes with Activation of TGFb-Signaling
tected in the absence of TGFb signaling. However, coex-Pathways
pression with an activated type I receptor resulted in(A) Smad7 blocks an immediate-early response to TGFb. HepG2
formation of Smad2/Smad4 heteromeric complexes,cells were cotransfected with the reporter gene (AR3-lux) alone
or with FAST1 in the absence or presence of Smad7. Cells were similar to previous observations (Figure 3A; Lagna et
incubated overnight with or without 100 pM of TGFb, and the relative al., 1996). In contrast, in cells coexpressing Smad7, we
luciferase activity was measured in cell lysates. Luciferase activity observed almost a complete block in TGFb-dependent
was normalized to b-galactosidase activity and was expressed as
association of Smad2 and Smad4.the mean 6 SD of triplicates from a representative experiment.
We also investigated whether Smad7 could disrupt(B) TGFb-dependent activation of GAL4/Smad2 is inhibited by
the nuclear localization of Smad2 in response to TGFbSmad7. HepG2 cells were cotransfected with the reporter gene
(pG5-E1b-lux) alone or with the indicated dose of GAL4/Smad2 signaling. HepG2 cells were transiently transfected with
in the absence (circle) or presence (square) of Smad7. Cells were Flag/Smad2 in the presence or absence of Smad7/HA
incubated overnight in the absence (open symbols) or presence and either wild-type or activated TbRI. The subcellular
(closed symbols) of 100 pM of TGFb, and the relative luciferase
localization of Flag/Smad2 was determined by immuno-activity was measured in cell lysates. Luciferase activity was normal-
fluorescence and confocal microscopy using a mouseized to b-galactosidase activity and was expressed as the mean 6
anti-Flag antibody. Similar to our previous observations,SD of triplicates from a representative experiment.
Smad2 was localized throughout the cell in unstimulated
cultures, and activation of TGFb signaling resulted in
nuclear accumulation of the protein. However, in theSince Smad2 is centrally involved in mediating TGFb
signaling, we investigated whether Smad7 might specifi- presence of Smad7, the nuclear accumulation of Smad2
in response to TGFb signals was blocked (Figure 3B).callydisrupt ligand-dependent activation of Smad2 tran-
scriptional activity. To test this, we employed a heterolo- For these studies, we simultaneously analyzed the ex-
pression of Smad7/HA using a rabbit anti-HA antibodygous transcriptional activation assay (Liu et al., 1996),
in which Smad2 is fused to the DNA-binding domain of and confirmed that Smad2 and Smad7 were coex-
pressed in the same cells (data not shown). Together,the yeast transcription factor GAL4. Expression of this
fusion protein in HepG2 cells mediated TGFb-depen- these data suggest that Smad7 inhibits TGFb signaling
by preventing Smad2 association with Smad4 and nu-dent induction of the heterologous promoter construct,
pG5-E1b-lux, which contains five GAL4 elements linked clear accumulation of the complex.
To explore the mechanism of Smad7 function, weto an E1b TATA box and a luciferase reporter gene. To
determine if Smad7 disrupts this response, pG5-E1b- first tested if it could engage Smad2 in nonproductive
heteromeric complexes. However, we were unable tolux was transfected into HepG2 cells together with in-
creasing amounts of GAL4/Smad2 expression vector detect any physical association of Smad7 with Smad2
Cell
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Figure 4. Smad7 Prevents Receptor-Dependent Phosphorylation of
Smad2
COS-1 cells were transiently transfected with the indicated combi-
nations of Flag/Smad2, Smad7/HA, and wild-type (WT) or activated
(A) TbRI. Cells were labeled with [32P]phosphate, and Flag/Smad2
was purified by immunoprecipitation with anti-Flag M2 antibody and
analyzed by SDS±PAGE and autoradiography (32PO4). The expres-
sion of Flag/Smad2, Smad7/HA, and TbRI/HA proteins was deter-
mined by immunoblotting total cell lysates using anti-Flag M2 anti-
body (a-Flag) or anti-HA antibody (a-HA) as indicated. The migration
of each protein is indicated on the left.
or Smad4 in either yeast or mammalian cells (data not
shown). Since phosphorylation of Smad2 by the TGFb
type I receptor is required for its activation and down-
stream functions, we investigated whether Smad7 inter-
feres with phosphorylation of the protein. To test this,
Smad2 was expressed in COS cells along with wild type
or constitutively activated TbRI, and phosphorylation of
the protein was analyzed by metabolic labeling with
[32P]phosphate. As described previously, coexpression
of Smad2 with activated TbRI resulted in a strong in-
crease in phosphate incorporation into the protein that
is due to receptor-mediated phosphorylation at the
Figure 3. Smad7 Blocks Smad2 Activation in Response to TGFb C-terminal serine residues (Figure 4; MacõÂas-Silva et al.,
Signaling
1996). In contrast, in the presence of Smad7, we ob-
(A) Smad7 disruptsTGFb-induced interaction of Smad2 with Smad4.
served little change in Smad2 phosphorylation (FigureHepG2 cells were transiently transfected with empty vector (2) or
4). We also investigated the phosphorylation of Smad7Flag/Smad2 and Smad4/HA together with wild-type (WT) or acti-
itself. Although Smad7 was expressed abundantly invated (A) TbRI either in the absence or presence of myc/Smad7.
Cell lysates were subjected to immunoprecipitation (IP) with anti- these cells, we detected only very low levels of basal
Flag M2 antibody (a-Flag) and then immunoblotted (blot) using anti- phosphorylation that were unaffected by TGFb signaling
HA antibody (a-HA). Expression of Smad2 was monitored by re- (data not shown). These results indicate that Smad7
probing the same membrane with a rabbit anti-Smad2 polyclonal
prevents TbRI-dependent phosphorylation of Smad2 inantisera (a-Smad2). To confirm equivalent levels of Smad4 expres-
intact cells but is not itself a target for TGFb-regulatedsion, aliquots of total lysates were immunoprecipitated using an
phosphorylation.anti-HA antibody and then immunoblotted with anti-HA antibody
(a-HA). Expression of Smad7 was measured in a similar manner
using an anti-myc monoclonal antibody (a-myc). Smad7 Interacts Stably with the TGFb Receptor
(B) Smad7 blocks the nuclear accumulation of Smad2 in response Phosphorylation of Smad2 in response to TGFb signal-
to TGFb signaling. HepG2 cells were transfected with Flag/Smad2
ing is mediated by the activated TGFb type I receptor.together with wild-type (TbRI) or activated (*TbRI) TGFb type I recep-
To test whether the inhibition of Smad2 phosphorylationtors, either in the absence (top four panels) or presence (bottom
occurs via interference with receptor function, we deter-four panels) of Smad7. Flag/Smad2 was detected by immunofluo-
rescence using anti-Flag M2antibody and FITC-conjugatedsecond- mined whether Smad7 directly interacts with the TGFb
ary antibody and analyzed by confocal microscopy. Smad2 is local- type I receptor. For this, we utilized a similar approach
ized prominently in the nucleus in the presence of activated TbRI. to our previous studies on Smad2 (MacõÂas-Silva et al.,
Coexpression with Smad7 blocks this nuclear accumulation, re-
1996). Briefly, COS cells were transfected with wild-typesulting in a diffuse staining pattern that is similar to controls.
or kinase-deficient versions of TbRII or TbRI, together
with Smad7 tagged at the carboxyl terminus with the
HA epitope. Receptors were affinity-labeled using
[125I]TGFb, and receptors coprecipitating with Smad7/
Smads as Antagonists of Ser/Thr Kinase Receptors
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to the endogenous receptors that are expressed in these
cells (Figure 5A; lower panel).
To confirm that Smad7 associates directly with the
type I receptor, we investigated interactions between
Smad7 and either wild-type or constitutively active TbRI.
COS-1 cells were transfected with myc-tagged Smad7
together with wild-type or activated TbRI/HA. Cell ly-
sates were then subjected to immunoprecipitation with
an anti-myc monoclonal antibody and the immunopre-
cipitates analyzed by immunoblotting using a rabbit
anti-HA polyclonal antibody. In cells cotransfected with
wild-type TbRI,a low levelof interactionbetween Smad7
and the receptor could be detected (Figure 5B). How-
ever, in cells expressing activated TbRI, we observed a
strong increase in the amount of type I receptor that
coprecipitated with Smad7. Together, these data dem-
onstrate that Smad7 associates stably with the TGFb
receptor complex via the activated type I kinase domain.
Since Smad7 binds to the receptor and blocks phos-
phorylation of Smad2, we examined whether Smad7
Figure 5. Smad7 Interacts Stably with Activated TbRI and Blocks alters association of Smad2 with the TGFb receptor. As
Smad2 Association with the Receptor
described previously, stable interaction between wild-
(A) Interaction of Smad7 with TGFb receptors. COS-1 cells were
type Smad2 and the receptor requires a kinase-deficienttransiently transfected with Smad7/HA alone or with the indicated
TbRI to trap the Smad2 substrate (MacõÂas-Silva et al.,combinations of wild-type (WT) or kinase-deficient (KR) TbRI and
1996). Thus, we expressed Smad2 together with TbRIITbRII. The cells were affinity labeled with 200 pM [125I]TGFb, and
lysates were subjected to immunoprecipitation with anti-HA anti- and TbRI(KR), either in the presence or absence of
body (a-HA IP). Affinity-labeled receptor complexes coprecipitating Smad7. Analysis of controls showed that affinity-labeled
with Smad7/HA were visualized by SDS±PAGE and autoradiogra- receptor complexes coprecipitated with Smad2. How-
phy. Similar levels of receptor expression were confirmed by analyz-
ever, in the presence of Smad7 expression, there wasing aliquots of total cell lysates by SDS±PAGE and autoradiography
a reduction in the amount of receptors that bound to(bottom panel, total).
Smad2. This decrease was specific for Smad7, since(B) Smad7 interacts preferentially with constitutively active TbRI.
COS-1 cells were transfected with combinations of myc-tagged Smad4, which does not interact with the TGFb receptor,
Smad7 and either wild-type (WT) or activated (A) HA-tagged TbRI had no effect in this assay (data not shown). These
as indicated. Cell lysates weresubjected to anti-myc immunoprecip- results suggest that Smad7 inhibits TGFb signaling by
itation using a monoclonal antibody followed by immunoblottng
preventing Smad2 access to the receptor.using anti-HA Y-11 polyclonal antibody (upper panel, a-HA blot).
Equivalent expression of Myc/Smad7 and TbRI/HA proteins was
confirmed by immunoblotting total cell lysates using anti-myc and
A Nonfunctional Mutant of Smad7 Does Notanti-HA monoclonal antibodies (bottom panel, a-myc and HA blot).
(C) Smad7 blocks association of Smad2 with the TGFb receptor Interact with the TGFb Receptor
complex. COS-1 cells were transfected with Flag/Smad2 and the To gain further evidence that Smad7 inhibits TGFb sig-
indicated combinations of TbRII, Smad7, and wild-type (WT) or ki- naling through its associations with the TGFb receptor,
nase-deficient (KR) TbRI. Cells were affinity labeled with [125I]TGFb
we investigated the function of a mutant version ofas described in (A) and lysates were subjected to anti-Flag immuno-
Smad7. Previous studies have demonstrated that a trun-precipitation. Receptor complexes coprecipitating with Smad2were
cation mutant of Smad4, identified in a pancreatic can-quantitated using a gamma counter. Data are expressed as a per-
centage of the counts in anti-Flag immunoprecipitates obtained cer, inactivates its function in TGFb signaling (Hahn et
from affinity-labeled cells transfected with TbRII, kinase-deficient al., 1996; Lagna et al., 1996; Zhang et al., 1996). We
TbRI, and Flag/Smad2 and represent the mean (6SD) of three inde- constructed an analogous mutant of Smad7 by introduc-
pendent experiments.
ing a stop codon after amino acid residue 408 (Figure
6A). To investigate the activity of this mutant, we
transfected HepG2 cells with p3TP-Lux and increasingHA were analyzed in anti-HA immunoprecipitates. In
cells cotransfected with wild-type TbRII and TbRI, re- amounts of wild-type Smad7 or Smad7(D408). Similar
to our previous observations, Smad7 inhibited TGFb-ceptor complexes could clearly be detected coprecipi-
tating with Smad7, and this interaction was comparable dependent induction of the 3TP promoter in a dose-
dependent fashion (Figure 6B). However, Smad7(D408),to levels obtained from cells expressing kinase-deficient
TbRI (Figure 5A). Furthermore, we detected minimal in- which was expressed efficiently (data not shown and
Figure 6C), had little or no ability toblock TGFb signalingteraction between Smad7 and receptor complexes as-
sembled in the presence of kinase-deficient TbRII(KR). even at the highest doses of transfected DNA.
To investigate how this truncation disrupts Smad7Since this mutation prevents transphosphorylation and
activation of TbRI, these results indicate that Smad7 activity, we examined whether Smad7(D408) interacts
with TGFb receptors. For these studies, wild-type orpreferentially binds to activated receptor I. During the
course of these experiments, we consistently observed mutant Smad7 was expressed in COS cells together
with TbRII and TbRI. Receptors were affinity-labeleda low level of interaction between receptors and Smad7
in cells transfected with TbRII. This may reflect binding using [125I]TGFb and complexes coprecipitating with
Cell
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Smad7/HA were analyzed quantitatively in a gamma
counter. In cells expressing wild-type Smad7, receptor
complexes labeled with [125I]TGFb were readily detected
coprecipitating with Smad7 protein (Figure 6C). How-
ever, in cells expressing Smad7(D408), there was a 10-
fold reduction, to near background levels, in the amount
of receptors that coprecipitated with the protein. We
also determined directly whether Smad7(D408) could
interfere with Smad2 association with the TGFb re-
ceptor. In contrast to wild-type Smad7, the mutant,
Smad7(D408), was unable to block association of
Smad2 with the TGFb receptor (Figure 6C). Together,
these data indicate that the stable interaction of Smad7
with the receptor is critical for its inhibitory activity in
TGFb signaling and strongly suggest that Smad7 is an
intracellular antagonist of the TGFb type I receptor ki-
nase domain.
Discussion
TGFb superfamily signaling is initiated when ligand in-
duces formation of a heteromeric complex of type II and
type I Ser/Thr kinase receptors (Attisano and Wrana,
1996; Weis-Garcia and Massague, 1996). Within this
complex, the type II receptor transphosphorylates re-
ceptor I in the GS domain, thus activating the type I
kinase domain that targets downstream substrates. Nu-
merous biochemical and genetic studies on the TGFb
superfamily have revealed that the MAD-related family
of signaling molecules are critical downstream media-
tors of these receptor complexes (Hoodless and Wrana,
1997). The direct phosphorylation of these proteins by
Ser/Thr kinase type I receptors followed by heteromeric
complex formation and nuclear accumulation has
emerged as a central theme in this signaling pathway.
Thus, Smad1 and 5 are specifically regulated by BMP
signaling, while Smad2 and 3 function in TGFb/activinFigure 6. Truncation of Smad7 Blocks Its Inhibitory Activity and
Disrupts Interaction with the TGFb Receptor pathways. Smad4 forms heteromeric complexes with
these receptor-regulated Smads and thus may fulfill a(A) The C-terminal amino acid sequence of Smad4 and Smad7 is
shown. The location of the premature stop codon of a mutant of common function in both signaling pathways. In this
Smad4 (D514; Hahn et al., 1996) and the corresponding truncation report, we investigate the role of Smad7 in TGFb signal-
in Smad7 (D408) are indicated.
ing. We demonstrate that Smad7 is an inhibitor of TGFb(B) TGFb-induced transcriptional activation of the 3TP promoter is
signaling, preventing heteromeric complex formationinhibited by wild-type but not truncated Smad7. HepG2 cells were
between Smad2 and Smad4 and the nuclear accumula-transiently transfected with p3TP-Lux, and increasing amounts of
either wild-type Smad7 (triangles) or the truncated version tion of Smad2 in response to TGFb signaling. Smad7
(Smad7D408; circles), and cells were incubated overnight in the functions by associating stably with the activated TGFb
presence (closed symbols) or absence (open symbols) of 100 pM type I receptor to block the interaction and phosphoryla-
of TGFb. The relative luciferase activity was measured in cell lysates
tion of Smad2. Furthermore, a truncation mutant ofand is expressed as the mean 6 SD of triplicates from a representa-
Smad7 that fails to associate with the receptor does nottive experiment.
inhibit TGFb signaling. These studies thus define a class(C) Smad7(D408) does not associate with the TGFb receptor and
does not block interaction of Smad2 with the receptor complex. of Smads that inhibit TGFb signaling by acting as intra-
COS-1 cells were transfected with indicated combinations of Flag/ cellular antagonists of the type I kinase domain of Ser/
Smad2, TbRII, wild-type (WT), or kinase-deficient (KR) TbRI and Thr kinase receptors.
wild-type (WT) or truncated (D408) Smad7/HA. Cells were affinity
labeled with [125I]TGFb as described in Figure 5A, and lysates were
subjected to anti-HA or anti-Flag immunoprecipitation. Receptor
Smad7 Is an Antagonist of the TbRI Kinase Domaincomplexes coprecipitating with Smad7 (left panel) or Smad2 (right
panel) were quantitated using a gamma counter. Data are expressed In TGFb signaling, the interaction of Smad2 with the
as amount relative to immunoprecipitates obtained from cells TGFb receptor results in its phosphorylation by the type
transfected with wild-type TGFb receptors for Smad7 (left panel) or I receptor, dissociation from the receptor complex, and
receptor complexes containing TbRI (KR) for Smad2 (right panel).
nuclear accumulation (MacõÂas-Silva et al., 1996). In con-Expression of Flag/Smad2, Smad7/HA and Smad7(D408)/HA was
trast to these transient interactions, we have shown thatassessed by immunoblotting total cell lysates from the transfected
cells with anti-Flag and anti-HA antibodies (bottom panel). Smad7 associates stably with the activated TGFb type
Smads as Antagonists of Ser/Thr Kinase Receptors
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I receptor. Previous studies on Smad2 showed that dis- Smad7 prevents the phosphorylation of Smad2, its as-
sociation with Smad4, and the nuclear accumulation ofsociation from the receptor required phosphorylation of
the protein. Thus,Smad7 is likely to be a general inhibitorthe protein on the C-terminal serine residues (MacõÂas-
of phosphorylated Smad2 function, as opposed to mod-Silva et al., 1996). Analysis of the sequence of Smad7
ulating subsets of Smad2-mediated responses. Thesereveals that while the protein possesses both an MH1
conclusions are consistent with the general block thatand MH2 domain, it does not contain the C-terminal
we observed in all of the transcriptional assays we em-SSXS motif, which is the target for receptor-mediated
ployed to study activation of Smad2 in response to TGFbphosphorylation of other Smads (MacõÂas-Silva et al.,
signaling. Interestingly, Smad3, which also functions in1996; Kretzchmar et al., 1997). Consistent with this, we
TGFb signaling, is over 90% identical to Smad2 in thewere unable to detect any phosphorylation of Smad7 in
MH2 domain and interacts with the TGFb receptor. Al-response to TGFb signaling, suggesting that this recep-
though this has not yet been directly investigated, ittor-associated Smad is not a substrate of the receptor.
is likely that Smad7 may function similarly to preventIn this regard, Smad7 functions similarly to the phos-
association and activation of Smad3 by the TGFb re-phorylation site mutant of Smad2 characterized pre-
ceptor.viously. This mutant, Smad2(3SA), which is not phos-
Our studies indicate one potential function for Smad7phorylated, interacts stably with the receptor and blocks
as an inhibitor of TGFb signaling. However, they do notTGFb signaling to endogenous MADR2 protein (MacõÂas-
rule out the possibility that this protein may have otherSilva et al., 1996). Thus, Smad7 represents a naturally
functions independent of its inhibitory role. The lack ofoccurring receptor kinase antagonist that functions to
an SSXS motif suggests this protein is unlikely to func-inhibit TGFb signaling by preventing access of Smad2
tion as a direct substrate of Ser/Thr kinase receptors.to the receptor kinase domain.
Smad7 was initially cloned based on its induction in
response to fluid shear stress in endothelial cells (Top-
per et al., 1996, 1997). It will be interesting to determineDeterminants within the MH2 Domain Are
whether, in addition to suppressing TGFb signaling, itRequired for Interaction of Smad7
may fulfill other functions in the normal physiology ofwith the TGFb Receptor
the vasculature.Receptor-regulated Smad proteins interact transiently
with the type I receptors. This may reflect an association
Negative Regulation of TGFb Signalingthat is restricted to the phosphotransferase reaction
Members of the TGFb superfamily are potent regulators
between the receptor kinase and its C-terminal peptide
of the growth and differentiation of a wide range of
substrate (Kretzchmar et al., 1997). However our obser-
cell types during development. Thus, the spatial and
vation that Smad7, which lacks the C-terminal region,
temporal control of their activity is critical to normal
associates stably with the receptor suggests an alterna- development and homeostasis. A wide range of mecha-
tive model in which the MH2 domain is the primary nisms exist to control the activity of these proteins, in-
determinant that mediates interaction of Smads with the cluding a range of extracellular antagonists that bind
receptor. In agreement with this, truncation of the MH2 the ligands and prevent activation of the signalingrecep-
domain of Smad7 disrupts binding to the receptor. tors. Our studies now define a novel intracellular mecha-
The potential role of the MH2 domain in mediating nism that can function to suppress TGFb signaling. Cell
receptor interactions suggests that determinants within type±specific regulation of intracellular receptor antago-
this domain may also be critical for establishing specific- nists could allow autonomous control of the response
ity. Biochemical and functional studies indicate that of cells to extracellular ligands in complex tissues. This
Smad1 and 5 function in BMP signaling and that Smad2 could provide for a precision in the control of TGFb
and 3 signal TGFb/activin responses. Thus, the molecu- signaling not afforded by secreted molecules. In particu-
lar basis for this high degree of specificity may reside lar, TGFb could differentially regulate cellular responses
in the MH2 domain as opposed to the C-terminal tail. in human vasculature, where Smad7 is expressed selec-
Of note, numerous mutations in the MH2 domain of tively in the endothelial layer (Topper et al., 1997).
receptor-regulated Smads have been identified in hu- In numerous tumors, resistance to TGFb is associated
man cancers and in the sma and Mad genes from C. with inactivating mutations that can occur either in the
elegans and Drosophila, respectively (Eppert et al., receptors or in components of the signaling pathways,
such as Smad2 or Smad4 (Eppert et al., 1996; Hahn et1996; Sekelsky et al., 1995; Savage et al., 1996). Many
al., 1996; Markowitz and Roberts, 1996). Here we haveof these mutations have been shown to block receptor-
identified a Smad protein that functions as an antagonistmediated phosphorylation of the protein (Eppert et al.,
of TGFb signaling. This suggests that amplified expres-1996; Hoodless et al., 1996), and it will be interesting to
sion of these proteins, as opposed to inactivation, mightdetermine whether these MH2 domain mutants function
act to suppress TGFb signals in tumors. Thus, it willby disrupting interaction of these proteins with the type
clearly be important in the future to investigate whetherI receptor kinase.
elevation of Smad7 expression may contribute to the
progression of human cancer.
Smad7 Functions at an Early Step to Inhibit
Experimental ProceduresTGFb Signaling
Our studies have defined Smad7 as an inhibitor that Construction of Expression Vectors
functions at a very early step in the TGFb signaling Human Smad7 was cloned from human umbilical vein endothelial
cells (HUVECs) isolated from multiple segments of normal-termpathway. As a direct antagonist of the receptor kinase,
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umbilical cords by differential display analysis as described pre- immunoprecipitation as described above. Receptor complexes in
the immunoprecipitates and in total cell lysates were visualized byviously (Topper et al., 1996) and is represented in the expressed
sequence tag database (clone numbers: EST54659, EST53587, and separation on SDS±PAGE gels and autoradiography.
EST24567). Myc/Smad7 was generated by introducing a Myc epi-
tope tag at the amino terminus of Smad7 by standard PCR-based Transcriptional Response Assay
protocols and was subcloned into pN8e-Myc/Smad7. Myc/Smad7 For TGFb-inducible luciferase reporter assays, HepG2 cells were
was then subcloned into pCMV5 using HindIII/XhoI sites to create transiently transfected with the reporter plasmid (p3TP-Lux),
pCMV5-Myc/Smad7. pCMV5-Smad7 was generated by subcloning pCMVb-gal and the indicated constructs or with empty vector alone.
the open reading frame of Smad7 into pCMV5 and was epitope To induce the luciferase reporter, cells were treated overnight in
tagged at the carboxyl terminus with the HA epitope, using standard 100 pM TGFb. Luciferase activity in cell lysates was measured using
approaches. The truncation mutant, pCMV5-Smad7(D408)/HA, was the luciferase assay system (Promega) in a Berthold Lumat LB 9501
constructed from pCMV5-Smad7 by introducing an HA epitope tag luminometer.
and stop codon after amino acid residue 408. The construction of For TGFb-inducible immediate early response gene transcription
pCMV5B-Flag/Smad2 has been described previously (Eppert et al., assays, HepG2 cells were transiently transfected with the reporter
1996). Mouse Smad4, cloned as described previously (MacõÂas-Silva plasmid (pAR3-lux), pCMVb-gal, and the indicated constructs or
et al., 1996), was tagged with the HAepitope at the carboxyl terminus with empty vector alone. Cells were treated overnight with or without
by PCR. The pAR3-lux construct, containing the luciferase reporter 100 pM TGFb, and luciferase activity in cell lysates was measured.
gene, was generated by subcloning a HindIII/XhoI insert of pSP72- For GAL4/Smad2 transcriptional assays, HepG2 cells were tran-
A3-CAT, (a kind gift from M. Whitman; Chen et al., 1996) into EcoRI/ siently transfected with the reporter plasmid (pG5-E1b-lux), pCMVb-
XhoI of pGL2-basic. The pG5-E1b-lux construct, containing the lu- gal, and the GAL4/Smad2 constructs or with empty vector alone.
ciferase reporter gene downstream of the DNA-binding elements of Cells were treated overnight with or without 100 pM TGFb, and
GAL4 and the E1b TATA box, was generated by subcloning an XhoI/ luciferase activity in cell lysates was measured. To determine trans-
EcoRI insert of pG5-E1b-CAT (a kind gift from A. Bonni) into XhoI/ fection efficiency in each assay, b-galactosidase activity assay was
HindIII of pGL2-Basic. pCMV5B-GAL4/Smad2, consisting of Smad2 performed as described (Sambrook et al., 1989), and luciferase
fused to the DNA-binding domain of GAL4 (amino acids 1±147), was assay results were normalized for b-galactosidase activity.
constructed by subcloning the GAL4/Smad2 insert from pGBT9-
Smad2 into pCMV5B using HindIII/XbaI sites. pCMV5B-GAL4 was Immunofluorescence
generated from pCMV5B-GAL4/Smad2 vector by digestion with HepG2 cells plated in Permanox chamber slides (Nunc) were tran-
EcoRI/XbaI. All constructs were confirmed by sequencing. siently transfected with various combinations of Smad7/HA, Flag/
Smad2 and wild-type or activated TbRI. Cells were fixed in 4%
paraformaldehyde and permeabilized as described previouslyCell Lines and Transfections
(Hoodless et al., 1996). Cells were blocked in 10% goat serum andMv1Lu and HepG2 cells were maintained in minimal essential media
incubated overnight at 48C with anti-HA polyclonal antibody, Y11 (1containing 10% fetal calf serum and nonessential amino acids, and
mg/ml; Santa Cruz Biotechnology) and anti-Flag monoclonal anti-COS-1 cells were grown in high glucose-Dulbecco's modified Ea-
body, M2 (10 mg/ml). Cells were washed in PBS and incubated withgle's media supplemented with 10% fetal calf serum. For transient
Texas Red (TR)±conjugated goat anti-rabbit IgG and fluoresceintransfections, HepG2 cells were seeded at 25% confluency in 24-
isothiocynate (FITC)±conjugated goat anti-mouse IgG (1:200 dilu-well plates and transfected overnight with 0.5 mg of DNA per well
tion; Jackson Immunologicals) as secondary antibodies (Hoodlessusing the calcium phosphate-DNA precipitation method as de-
et al., 1996). Images were obtained using a Leica confocal micro-scribed previously (Hoodless et al., 1996). For transfections in COS-1
scope.and Mv1Lu, cells were seeded at 50%±70% confluency and were
transfected with DEAE-dextran as described previously (Attisano et
al., 1996). Expression of Smad2, Smad4, Smad7, and TbRI proteins Acknowledgments
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